Nature of Business and Significant Accounting Policies - Schedule of Restatement of Previously Issued Consolidated Financial Statements (Details)

v3.20.4

Nature of Business and Significant Accounting Policies - Schedule of Restatement of Previously Issued Consolidated Financial Statements (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended																												12 Months Ended										36 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Sep. 30, 2017		Jun. 30, 2017		Mar. 31, 2017		Sep. 30, 2016		Jun. 30, 2016		Mar. 31, 2016		Sep. 30, 2015		Jun. 30, 2015		Mar. 31, 2015		Sep. 30, 2014		Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017		Dec. 31, 2016		Dec. 31, 2015		Dec. 31, 2014		Dec. 31, 2019	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014
Cash and cash equivalents																																								$ 2,321	$ 6,068
Accounts receivable, net																																								10,338	9,483
Other current assets																																								3,851	2,170
Total current assets																																								16,510	17,721
Property and equipment, net																																								6,814	837
Other intangible assets, net																																								15,849	12,538
Goodwill																																								8,433
Operating lease right of use assets																																								3,892
Other long-term assets																																								42	31
Total assets																																								51,540	31,127	36,619				$ 25,136				$ 64,741				$ 115,211
Accounts payable																																								4,709	1,059
Accrued salary and bonus																																								2,341	1,544
Other accrued expenses																																								9,476	5,148
Current liabilities from discontinued operations																																								766	918
Total current liabilities																																								17,292	8,669
Contingent consideration																																								2,391	2,693
Operating lease liabilities, net of current portion																																								2,591
Line of credit																																								3,000
Other long-term liabilities																																								4,573	4,319
Total liabilities																																								29,847	15,681
Preferred stock, $.01 par value; 5,000,000 shares authorized, 270 shares issued and outstanding																																								26,172
Common stock, $.01 par value; 100,000,000 shares authorized; 3,932,370 shares issued and 3,920,589 shares outstanding;																																								393	287
Additional paid-in capital																																								182,514	175,820
Accumulated deficit																																								(185,665)	(158,981)
Treasury stock, at cost (11,781 shares)																																								(1,721)	(1,680)
Total stockholders' equity	$ 6,030	$ 13,346	$ 13,346	$ 18,372	$ 18,799	$ 21,406	$ 21,406	$ 22,703	$ 19,484		$ 19,532		$ 7,843		$ (5,979)		$ 2,003		$ 4,826		$ 3,400		$ 8,347		$ 15,183		$ 25,306		$ (4,479)	$ 22,891	$ (10,111)		$ (10,111)		$ 10,067		$ 19,427		$ (10,111)	(4,479)	15,446	22,891	19,484	19,532	7,843	(10,111)	(5,979)	2,003	4,826	10,067	3,400	8,347	15,183	19,427	25,306
Total liabilities and stockholders' equity																																								25,368	31,127
Total liabilities, preferred stock and stockholders' equity																																								51,540	31,127
Revenue, net																													24,220	21,896
Cost of revenue																													15,888	10,197
Gross profit																													8,332	11,699
Sales and marketing																													11,116	8,421
Research and development																													2,810	2,124
General and administrative																													14,363	8,676
Acquisition related expense																													2,534
Acquisition related amortization expense																													3,989	3,589
Change in fair value of contingent consideration																													(44)	1,522
Total operating expenses																													34,768	24,332
Operating loss																													(26,436)	(12,633)
Accretion expense																													(440)	(331)
Other income (expense), net																													196	263
Loss from continuing operations before tax																													(26,680)	(12,701)
(Benefit) provision for income taxes																													(28)	18
Loss from continuing operations																													(26,652)	(12,719)
Income from discontinued operations, net of tax																													(88)	16
Net loss	(10,663)	(7,446)	(5,304)	(3,326)	(4,299)	(3,126)	(2,001)	(3,277)	$ (3,400)		$ (6,390)		$ 2,330		$ (8,003)		$ (2,844)		$ (5,296)		$ (5,405)		$ (7,488)		$ (4,614)		$ (4,454)		(26,740)	(12,703)	$ 12,553		$ (22,003)		$ (13,623)		$ (16,768)
Less dividends on preferred stock																													(429)
Net loss attributable to common stockholders																													$ (27,169)	$ (12,703)
From continuing operations																													$ (7.23)	$ (4.52)
From discontinued operations																													(0.02)
Net loss per basic and diluted share of common stock									$ (1.54)	[1]	$ (6.61)	[1]	$ 5.32	[1]	$ (43.97)	[1]	$ (15.63)	[1]	$ (29.75)	[1]	$ (34.43)	[1]	$ (49.26)	[1]	$ (30.76)	[1]	$ (29.89)	[1]	$ (7.25)	$ (4.52)	$ (7.96)	[1]	$ (120.90)	[1]	$ (87.95)	[1]	$ (112.53)	[1]
Balance	6,030	13,346	18,372	15,446	18,799	21,406	22,703	22,891	$ 19,532		$ 7,843		$ (10,111)		$ 2,003		$ 4,826		$ 10,067		$ 8,347		$ 15,183		$ 19,427				$ 15,446	$ 22,891	$ (10,111)		$ 10,067		$ 19,427				(10,111)
Common stock issued			73	1	594	143	285	1
Common stock issued through offering, net of expenses				5,962
Common stock issued through market sales, net of expenses	228
Treasury stock purchased	(9)			(32)				(9)
Stock-based compensation expense	289	205	205	266	352		419	597
Dividends accrued	(354)	(75)
Adoption of ASC 606								2,500
Adoption of ASC 842				55
Balance	(4,479)	6,030	13,346	18,372	15,446	18,799	21,406	22,703	19,484		19,532		7,843		(5,979)		2,003		4,826		3,400		8,347		15,183		$ 25,306		(4,479)	15,446	22,891		(10,111)		10,067		$ 19,427		(4,479)
Depreciation and amortization																													4,524	3,801
Interest accretion																													440	331
Bad debt expense																													499
Reversal of DOJ accrual																														(350)
Mark to market on warrants																													(279)	112
Stock-based compensation																													1,535	2,270
Deferred income taxes																													18
Change in estimate on collectability of accounts receivable																													3,479
Other gains and expenses, net																													18
Increase in accounts receivable																													(1,102)	(3,546)
Decrease (increase) in other current assets																													129	(501)
Increase in other long-term assets																													(11)
(Decrease) increase in accounts payable																													(938)	668
Increase in accrued salaries and bonus																													362	150
Decrease in accrued liabilities																													(1,301)	(345)
Increase (decrease) in long-term liabilities																													454	(82)
Net cash used in operating activities																													(18,957)	(8,673)
Acquisition of Biopharma, net of cash acquired																													(13,829)
Purchase of property and equipment																													(131)	(449)
Sale of property and equipment																													13
Net cash used in investing activity																													(13,947)	(449)
Issuance of common stock, net of expenses																													6,478
Issuance of preferred stock, net of expenses																													25,744
Payment of CGIX note and related interest																													6,024
Borrowings on Line of Credit																													3,000
Cash paid for repurchase of restricted shares																													(41)	(9)
Net cash provided by (used in) financing activities																													29,157	(9)
Net decrease in cash and cash equivalents																													(3,747)	(9,131)
Cash and cash equivalents - beginning of year				6,068				15,199																					6,068	15,199
Cash and cash equivalents - end of year	2,321				6,068																								2,321	6,068	15,199								2,321
Common Stock [Member]
Total stockholders' equity	393	383	383	382	287	283	282	279																					393	287	278								$ 393	393	287	278
Net loss
Balance	$ 383	$ 383	$ 382	$ 287	$ 283	$ 282	$ 279	$ 278																					$ 287	$ 278
Balance, shares	3,829,000	3,829,000	3,819,000	2,877,000	2,837,000	2,827,000	2,794,000	2,790,000																					2,877,000	2,790,000
Common stock issued			$ 1	$ 1	$ 4	$ 1	$ 3	$ 1
Common stock issued, shares	5,000		10,000	9,000	40,000	10,000	33,000	4,000																															3,700,000
Common stock issued through offering, net of expenses				$ 94
Common stock issued through offering, net of expenses, shares				933,000
Common stock issued through market sales, net of expenses	$ 10
Common stock issued through market sales, net of expenses, shares	98,000
Balance	$ 393	$ 383	$ 383	$ 382	$ 287	$ 283	$ 282	$ 279																					$ 393	$ 287	$ 278								$ 393
Balance, shares	3,932,000	3,829,000	3,829,000	3,819,000	2,877,000	2,837,000	2,827,000	2,794,000																					3,932,000	2,877,000	2,790,000								3,932,000
Treasury Stock [Member]
Total stockholders' equity	$ (1,721)	$ (1,712)	$ (1,712)	$ (1,712)	$ (1,680)	$ (1,680)	$ (1,680)	$ (1,680)																					$ (1,721)	$ (1,680)	$ (1,671)								$ (1,721)	(1,721)	(1,680)	(1,671)
Net loss
Balance	$ (1,712)	$ (1,712)	$ (1,712)	$ (1,680)	$ (1,680)	$ (1,680)	$ (1,680)	$ (1,671)																					$ (1,680)	$ (1,671)
Balance, shares	10,000	10,000	10,000	7,000	7,000	7,000	7,000	6,000																					7,000	6,000
Treasury stock purchased	$ (9)			$ (32)				$ (9)
Treasury stock purchased, shares	2,000			3,000				1,000
Balance	$ (1,721)	$ (1,712)	$ (1,712)	$ (1,712)	$ (1,680)	$ (1,680)	$ (1,680)	$ (1,680)																					$ (1,721)	$ (1,680)	$ (1,671)								$ (1,721)
Balance, shares	12,000	10,000	10,000	10,000	7,000	7,000	7,000	7,000																					12,000	7,000	6,000								12,000
Additional Paid-in Capital [Member]
Total stockholders' equity	$ 182,514	$ 182,231	$ 182,231	$ 181,954	$ 175,820	$ 174,878	$ 174,360	$ 173,659																					$ 182,514	$ 175,820	$ 173,062								$ 182,514	182,514	175,820	173,062
Balance	182,361	182,231	181,954	175,820	174,878	174,360	173,659	173,062																					175,820	173,062
Common stock issued			72		598	144	282
Common stock issued through offering, net of expenses				5,868
Common stock issued through market sales, net of expenses	218
Stock-based compensation expense	289	205	205	266	344	374	419	597
Dividends accrued	(354)	(75)
Balance	182,514	182,361	182,231	181,954	175,820	174,878	174,360	173,659																					182,514	175,820	173,062								182,514
Accumulated Deficit [Member]
Total stockholders' equity	(185,665)	(167,556)	(167,556)	(162,252)	(158,981)	(154,682)	(151,556)	(149,555)																					(185,665)	(158,981)	(148,778)								(185,665)	(185,665)	(158,981)	(148,778)
Net loss	(10,663)	(7,446)	(5,304)	(3,326)	(4,299)	(3,126)	(2,001)	(3,277)
Balance	(175,002)	(167,556)	(162,252)	(158,981)	(154,682)	(151,556)	(149,555)	(148,778)																					(158,981)	(148,778)
Adoption of ASC 606								2,500
Adoption of ASC 842				55
Balance	(185,665)	(175,002)	(167,556)	(162,252)	(158,981)	(154,682)	(151,556)	(149,555)																					(185,665)	(158,981)	(148,778)								(185,665)
As Previously Reported [Member]
Cash and cash equivalents																																								2,321	6,068
Accounts receivable, net																																								10,197	9,483
Other current assets																																								3,851	2,170
Total current assets																																								16,369	17,721
Property and equipment, net																																								6,814	837
Other intangible assets, net																																								33,501	29,853
Goodwill																																								8,433
Operating lease right of use assets																																								3,892
Other long-term assets																																								42	31
Total assets																																								69,051	48,442	53,598				41,778				67,712				115,906
Accounts payable																																								4,812	1,059
Accrued salary and bonus																																								2,341	1,424
Other accrued expenses																																								9,379	5,091
Current liabilities from discontinued operations																																								766	918
Total current liabilities																																								17,298	8,492
Contingent consideration																																								2,391	2,693
Operating lease liabilities, net of current portion																																								2,591
Line of credit																																								3,000
Other long-term liabilities																																								4,573	4,319
Total liabilities																																								29,853	15,504
Preferred stock, $.01 par value; 5,000,000 shares authorized, 270 shares issued and outstanding																																								29,853
Common stock, $.01 par value; 100,000,000 shares authorized; 3,932,370 shares issued and 3,920,589 shares outstanding;																																								393	287
Additional paid-in capital																																								182,514	175,820
Accumulated deficit																																								(168,160)	(141,489)
Treasury stock, at cost (11,781 shares)																																								(1,721)	(1,680)
Total stockholders' equity	13,026			32,938	32,938			39,869	36,378		36,342		24,569		(1,479)		5,993		8,306		5,861		10,298		16,624		25,424		32,938	39,869	6,531		6,531		13,038		20,122		6,531	13,026	32,938	39,869	$ 36,378	$ 36,342	$ 24,569	$ 6,531	$ (1,479)	$ 5,993	$ 8,306	$ 13,038	$ 5,861	$ 10,298	$ 16,624	$ 20,122	$ 25,424
Total liabilities and stockholders' equity																																								42,879
Total liabilities, preferred stock and stockholders' equity																																								69,051	48,442
Revenue, net																													24,079	21,896
Cost of revenue																													15,888	10,197
Gross profit																													8,191	11,699
Sales and marketing																													11,116	8,421
Research and development																													2,810	2,124
General and administrative																													14,546	8,499
Acquisition related expense																													2,534
Acquisition related amortization expense																													3,652	3,252
Change in fair value of contingent consideration																													(44)	1,522
Total operating expenses																													34,614	23,818
Operating loss																													(26,423)	(12,119)
Accretion expense																													(440)	(331)
Other income (expense), net																													196	263
Loss from continuing operations before tax																													(26,667)	(12,187)
(Benefit) provision for income taxes																													(28)	18
Loss from continuing operations																													(26,639)	(12,205)
Income from discontinued operations, net of tax																													(88)	16
Net loss									$ (3,316)		$ (6,306)		$ 2,414		$ (7,493)		$ (2,334)		$ (4,786)		$ (4,895)		$ (6,978)		$ (3,868)		$ (4,336)		(26,727)	$ (12,189)	$ (12,216)		$ (8,332)		$ (11,356)		$ (16,073)
Less dividends on preferred stock																													(429)
Net loss attributable to common stockholders																													$ (27,156)
From continuing operations																													$ (7.23)	$ (4.33)
From discontinued operations																													(0.02)
Net loss per basic and diluted share of common stock									$ (1.51)	[1]	$ (6.53)	[1]	$ 5.51	[1]	$ (41.17)	[1]	$ (12.82)	[1]	$ (26.89)	[1]	$ (31.18)	[1]	$ (45.91)	[1]	$ (25.79)	[1]	$ (29.10)	[1]	$ (7.25)	$ (4.33)	$ (7.75)	[1]	$ (45.78)	[1]	$ (73.26)	[1]	$ (107.87)	[1]
Balance				32,938				39,869	$ 36,342		$ 24,569		$ 6,531		$ 5,993		$ 8,306		$ 13,038		$ 10,298		$ 16,624		$ 20,122				$ 32,938	$ 39,869	$ 6,531		$ 13,038		$ 20,122				6,531
Balance	13,026				32,938				$ 36,378		$ 36,342		$ 24,569		$ (1,479)		$ 5,993		$ 8,306		$ 5,861		$ 10,298		$ 16,624		$ 25,424		13,026	32,938	39,869		$ 6,531		$ 13,038		$ 20,122		13,026
Depreciation and amortization																													4,187	3,464
Interest accretion																													440	331
Bad debt expense																													499
Reversal of DOJ accrual																														(350)
Mark to market on warrants																													(279)	112
Stock-based compensation																													1,535	2,270
Deferred income taxes																													18
Change in estimate on collectability of accounts receivable																													3,479
Other gains and expenses, net																													18
Increase in accounts receivable																													(961)	(3,546)
Decrease (increase) in other current assets																													129	(501)
Increase in other long-term assets																													(11)
(Decrease) increase in accounts payable																													(835)	668
Increase in accrued salaries and bonus																													482	30
Decrease in accrued liabilities																													(1,341)	(402)
Increase (decrease) in long-term liabilities																													454	(82)
Net cash used in operating activities																													(18,957)	(8,673)
Acquisition of Biopharma, net of cash acquired																													(13,829)
Purchase of property and equipment																													(131)	(449)
Sale of property and equipment																													13
Net cash used in investing activity																													(13,947)	(449)
Issuance of common stock, net of expenses																													6,478
Issuance of preferred stock, net of expenses																													25,744
Payment of CGIX note and related interest																													(6,024)
Borrowings on Line of Credit																													3,000
Cash paid for repurchase of restricted shares																													(41)	(9)
Net cash provided by (used in) financing activities																													29,157	(9)
Net decrease in cash and cash equivalents																													(3,747)	(9,131)
Cash and cash equivalents - beginning of year				6,068				15,199																					6,068	15,199
Cash and cash equivalents - end of year	2,321				6,068																								2,321	6,068	15,199								2,321
As Previously Reported [Member] | Common Stock [Member]
Total stockholders' equity	393	383	383	382	283	283	282	279																					393	278	278								393	393	287	278
Balance	$ 383	$ 383	$ 382	$ 287	$ 283	$ 282	$ 279	$ 278																					$ 287	$ 278
Balance, shares	3,829,000	3,829,000	3,819,000	2,877,000	2,837,000	2,827,000	2,794,000	2,790,000																					2,877,000	2,790,000
Common stock issued			$ 1	$ 1	$ 4	$ 1	$ 3	$ 1
Common stock issued, shares	5,000		10,000	9,000	40,000	10,000	33,000	4,000
Common stock issued through offering, net of expenses				$ 94
Common stock issued through offering, net of expenses, shares				933,000
Common stock issued through market sales, net of expenses	$ 10
Common stock issued through market sales, net of expenses, shares	98,000
Balance	$ 393	$ 383	$ 383	$ 382	$ 287	$ 283	$ 282	$ 279																					$ 393	$ 287	$ 278								$ 393
Balance, shares	3,932,000	3,829,000	3,829,000	3,819,000	2,877,000	2,837,000	2,827,000	2,794,000																					3,932,000	2,877,000	2,790,000								3,932,000
As Previously Reported [Member] | Treasury Stock [Member]
Total stockholders' equity	$ (1,721)	$ (1,712)	$ (1,712)	$ (1,712)	$ (1,680)	$ (1,680)	$ (1,680)	$ (1,671)																					$ (1,721)	$ (1,671)	$ (1,671)								$ (1,721)	(1,721)	(1,680)	(1,671)
Balance	$ (1,712)	$ (1,712)	$ (1,712)	$ (1,680)	$ (1,680)	$ (1,680)	$ (1,680)	$ (1,671)																					$ (1,680)	$ (1,671)
Balance, shares	10,000	10,000	10,000	7,000	7,000	7,000	7,000	6,000																					7,000	6,000
Treasury stock purchased	$ (9)			$ (32)				$ (9)
Treasury stock purchased, shares	2,000			3,000				1,000
Balance	$ (1,721)	$ (1,712)	$ (1,712)	$ (1,712)	$ (1,680)	$ (1,680)	$ (1,680)	$ (1,680)																					$ (1,721)	$ (1,680)	$ (1,671)								$ (1,721)
Balance, shares	12,000	10,000	10,000	10,000	7,000	7,000	7,000	7,000																					12,000	7,000	6,000								12,000
As Previously Reported [Member] | Additional Paid-in Capital [Member]
Total stockholders' equity	$ 182,514	$ 182,361	$ 182,231	$ 181,954	$ 174,878	$ 174,878	$ 174,360	$ 173,659																					$ 182,514	$ 173,062	$ 173,062								$ 182,514	182,514	175,820	173,062
Balance	182,361	182,231	181,954	175,820	174,878	174,360	173,659	$ 173,062																					175,820	173,062
Common stock issued			72		598	144	282
Common stock issued through offering, net of expenses				5,868
Common stock issued through offering, net of expenses, shares
Common stock issued through market sales, net of expenses	218
Stock-based compensation expense	289	205	205	266	344	374	419	$ 597
Dividends accrued	(354)	(75)
Balance	182,514	182,361	182,231	181,954	175,820	174,878	174,360	173,659																					182,514	175,820	173,062								182,514
As Previously Reported [Member] | Accumulated Deficit [Member]
Total stockholders' equity	(168,160)	(157,435)	(150,073)	(144,853)	(137,452)	(137,452)	(134,410)	(132,493)																					(168,160)	(131,800)	(131,800)								(168,160)	(168,160)	(141,489)	(131,800)
Net loss	(10,725)	(7,362)	(5,220)	(3,419)	(4,037)	(3,042)	(1,917)	(3,193)
Balance	(157,435)	(150,073)	(144,853)	(141,489)	(137,452)	(134,410)	(132,493)	(131,800)																					(141,489)	(131,800)
Adoption of ASC 606								2,500
Adoption of ASC 842				55
Balance	(168,160)	(157,435)	(150,073)	(144,853)	(141,489)	(137,452)	(134,410)	(132,493)																					(168,160)	(141,489)	(131,800)								(168,160)
Restatement Amount [Member]
Cash and cash equivalents
Accounts receivable, net																																								141
Other current assets
Total current assets																																								141
Property and equipment, net
Other intangible assets, net																																								(17,652)	(17,315)
Goodwill
Operating lease right of use assets
Other long-term assets
Total assets																																								(17,511)	(17,315)
Accounts payable																																								(103)
Accrued salary and bonus																																									120
Other accrued expenses																																								97	57
Current liabilities from discontinued operations
Total current liabilities																																								(6)	177
Contingent consideration
Operating lease liabilities, net of current portion
Line of credit
Other long-term liabilities
Total liabilities																																								(6)	177
Preferred stock, $.01 par value; 5,000,000 shares authorized, 270 shares issued and outstanding
Common stock, $.01 par value; 100,000,000 shares authorized; 3,932,370 shares issued and 3,920,589 shares outstanding;
Additional paid-in capital
Accumulated deficit																																								(17,505)	(17,492)
Treasury stock, at cost (11,781 shares)
Total stockholders' equity	(17,505)			(17,492)	(17,492)																								(17,505)	(17,492)									(17,505)	(17,505)	(17,492)
Total liabilities and stockholders' equity																																								(17,511)
Total liabilities, preferred stock and stockholders' equity																																								(17,511)	(17,315)
Revenue, net																													141
Cost of revenue
Gross profit																													141
Sales and marketing
Research and development
General and administrative																													(183)	177
Acquisition related expense
Acquisition related amortization expense																													337	337
Change in fair value of contingent consideration
Total operating expenses																													154	514
Operating loss																													(13)	(514)
Accretion expense
Other income (expense), net
Loss from continuing operations before tax																													(13)	(514)
(Benefit) provision for income taxes
Loss from continuing operations																													(13)	(514)
Income from discontinued operations, net of tax
Net loss																													(13)	$ (514)
Less dividends on preferred stock
Net loss attributable to common stockholders																													$ (13)
From continuing operations																													$ (0.00)	$ (0.19)
From discontinued operations
Net loss per basic and diluted share of common stock																													$ (0.00)	$ (0.19)
Balance				(17,492)																									$ (17,492)
Balance	(17,505)				(17,492)																								(17,505)	$ (17,492)									(17,505)
Depreciation and amortization																													337	337
Interest accretion
Bad debt expense
Reversal of DOJ accrual
Mark to market on warrants
Stock-based compensation
Deferred income taxes
Change in estimate on collectability of accounts receivable
Other gains and expenses, net
Increase in accounts receivable																													(141)
Decrease (increase) in other current assets
Increase in other long-term assets
(Decrease) increase in accounts payable																													(103)
Increase in accrued salaries and bonus																													(120)	120
Decrease in accrued liabilities																													40	57
Increase (decrease) in long-term liabilities
Net cash used in operating activities
Acquisition of Biopharma, net of cash acquired
Purchase of property and equipment
Sale of property and equipment
Net cash used in investing activity
Issuance of common stock, net of expenses
Issuance of preferred stock, net of expenses
Payment of CGIX note and related interest
Borrowings on Line of Credit
Cash paid for repurchase of restricted shares
Net cash provided by (used in) financing activities
Net decrease in cash and cash equivalents
Cash and cash equivalents - beginning of year
Cash and cash equivalents - end of year
Restatement Amount [Member] | Common Stock [Member]
Total stockholders' equity
Balance
Balance, shares
Common stock issued
Common stock issued, shares
Common stock issued through offering, net of expenses
Common stock issued through offering, net of expenses, shares
Common stock issued through market sales, net of expenses
Common stock issued through market sales, net of expenses, shares
Balance
Balance, shares
Restatement Amount [Member] | Treasury Stock [Member]
Total stockholders' equity
Balance
Balance, shares
Treasury stock purchased
Treasury stock purchased, shares
Balance
Balance, shares
Restatement Amount [Member] | Additional Paid-in Capital [Member]
Total stockholders' equity
Balance
Common stock issued
Common stock issued through offering, net of expenses
Common stock issued through offering, net of expenses, shares
Common stock issued through market sales, net of expenses
Stock-based compensation expense
Dividends accrued
Balance
Restatement Amount [Member] | Accumulated Deficit [Member]
Total stockholders' equity	(17,505)	(17,567)	(17,483)	(17,399)	(17,230)	(17,230)	(17,146)	(17,062)																					(17,505)	(16,978)	(16,978)								(17,505)	$ (17,505)	$ (17,492)	$ (16,978)
Net loss	62	(84)	(84)	93	(262)	(84)	(84)	(84)
Balance	(17,567)	(17,483)	(17,399)	(17,492)	(17,230)	(17,146)	(17,062)	(16,978)																					(17,492)	(16,978)
Adoption of ASC 606
Adoption of ASC 842
Balance	$ (17,505)	$ (17,567)	$ (17,483)	$ (17,399)	$ (17,492)	$ (17,230)	$ (17,146)	$ (17,062)																					$ (17,505)	$ (17,492)	$ (16,978)								$ (17,505)
[1] Adjusted for reverse stock splits since the filing of the original financial statements.